Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis

British Medical Journal, April 8, 2000 by Darren M Ashcroft, Alain Li Wan Po, Hywel C Williams, Christopher E M Griffiths

[16] Lehmann P, Kerscher M. Combination phototherapy of psoriasis with calcipotriene and narrow-band (311 nm) UVB [letter]. J Am Acad Dermatol 1997;36:501-2.

[17] Kerscher M, Volkenandt M, Plewig G, Lehmann P. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB [letter]. Lancet 1993;342:923.

[18] Kerscher M, Lehmann P, Plewig G. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB-light [abstract].J Invest Dermatol 1996 ;1:10 7.

[19] Austad J. A comparative study of calcipotriol ointment in combination with UVB phototherapy and calcipotriol ointment alone in the treatment of psoriasis vulgaris [abstract]. Presented at the 27th Nordic Dermatology Congress. Finland, 1995.

[20] van de Kerkhof PCM. Calcipotriol cream and concurrent corticosteroids in psoriasis [abstract]. J Eur Acad Dermatol Venereol 1995;5(suppl 1):S 184.

[21] Bourke JE Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol 1993; 18:504-6.

[22] Berardesca E, Vignoli GP, Farinelli N, Viguini M, Distante F, Rabbiosi G. Non-invasive evaluation of topical calcipotriol versus clobetasol in the treatment of psoriasis. Acta Derm Venereol (Stockh) 1994;74:302-4.

[23] Baadsgaard O, Traulsen J, Roed-Petersen J, Jakobsen HB. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatol Treat 1995;6:145-50.

[24] Austad J. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis [abstract]. Aust J Dermatol 1997;38(suppl 2):45.

[25] Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin [D.sub.3] analogue (MC903) in a double-blind study. Br J Dermatol 1988;119:223-30.

[26] Staberg B, Roed-Petersen J, Menne T. Efficacy of topical treatment in psoriasis with MC903, a new vitamin D analogue. Acta Derm Venereol (Stockh) 1989;69:147-50.

[27] Schwartzel E, Blum R, Siskin S, Epinette W. A parallel group study evaluating the safety of 30 gram per day dosing of calcipotriene (BMS181161/MC903) ointment and its vehicle in patients with plaque psoriasis [abstract]. Presented at the 54th annual meeting of the American Academy of Dermatology. Washington, DC;1996:P-287.

[28] Kose O. Calcipotriol ointment vs clobetasol solution in scalp psoriasis [letter]. J Dermatol Treat 1997;8:287.

[29] Mallett RB, Coulson IH, Purkis PE, Leigh IM, Holden CA. An immuno-histochemical analysis of the changes in the immune infiltrate and keratin expression in psoriasis treated with calcipotriol compared with betamethasone ointment Br J Dermatol 1990; 123:837.

[30] Arevalo A, Vega-Lopez E Calcipotriol versus coal tar in Mexican patients with psoriasis [abstract]. J Eur Acad Dermatol Venereol 1995;5(suppl 1):S92.

[31] Katz HI, Lindholm JS, Wilde M, Siskin S, Wehr RW, Koeowald M, et al. A pilot, double-blind, bilateral, paired comparison of the efficacy, safety, and atrophogenic potential of calcipotriene ointment 0.005% versus its vehicle in the treatment of plaque psoriasis utilizing clinical evaluations and bioinstrumentation [abstract]. Presented at the 54th annual meeting of the American Academy of Dermatology. Washington, DC;1996:P-293.